Guangzhou, March 3 (Zhongxin Net) (Reporter Cai Minjie) Multiple myeloma (MM) is the second most common hematological tumor, and in China, the age of onset is mostly over 27 years old. With the development of the aging population, the incidence rate is on the rise.
"In recent years, despite the rapid development of innovative treatment methods for MM and the increase in first-line treatment options, patients are still facing the problem of relapse." Liu Qiqi, dean of the Institute of Hematology and director of the Institute of Hematology of Southern Medical University, recently pointed out, "With the recurrence, the remission rate of patients will be lower and lower, and the survival time will be shorter and shorter, so for patients with relapsed/refractory MM, drugs with superior efficacy should be selected as soon as possible to help prolong survival to the greatest extent." ”
On the occasion of the "International Myeloma Care Month" in March, the 3 International Myeloma Care Month Patient Care Salon was successfully held in Guangzhou, initiated by the Guangdong Anti-Cancer Association and the Science Popularization Subcommittee of the Chinese Anti-Cancer Association, together with the Southern Hospital of Southern Medical University and the Myeloma Home. At the meeting, several experts called on the community to pay attention to the unmet needs of patients with multiple myeloma.
At present, MM is still difficult to cure, a large number of patients will relapse due to disease progression, the follow-up survival is not optimistic, and the burden of disease is heavy. According to the "2022 Survey Report on the Survival of Multiple Myeloma Patients in China's First-tier Cities", more than 30% of MM patients surveyed said that the disease seriously affected work and life, and more than 60% of patients had poor psychological conditions. At the same time, the majority of patients' families also need to share the storm with patients, and about 94% of patients need family or caregiver care.
There are many innovative drugs in the field of hematological cancer in the world, but not all drugs have been approved for marketing in China, and the treatment options of patients are still limited, and their needs still need to be met.
Relying on the "Hong Kong-Macao Pharmacy and Equipment Connect" policy in the Guangdong-Hong Kong-Macao Greater Bay Area, a new generation of CD38-targeted monoclonal monoclonal antibodies was approved and introduced into the University of Hong Kong-Shenzhen Hospital. "MM recurrence is inevitable, so a better approach to first-line treatment is needed to improve the quality of life of patients, reduce the frequency of recurrence, and bring longer survival to patients with relapse." Zhu Zhimei, director of the Department of Hematology at the University of Hong Kong-Shenzhen Hospital, said that under the current strategy of MM recurrence treatment combination, conversion and upgrade, the introduction of new CD38 has brought the possibility of deeper remission and reduced drug resistance.
Liu Qiqi said: "In the future, we also hope to continue to promote the early landing of innovative drugs for hematological oncology in the Greater Bay Area, enrich the treatment options of patients, benefit more hematological cancer patients, and help improve the overall diagnosis and treatment level of hematological oncology in the Greater Bay Area." (End)